In a subsequent analysis of raw transcriptomic datasets originating from other studies, the authors noted that human breast cancer cell lines with acquired anticancer drug resistance share as a common feature the increased expression of MAO-A, which correlates with poor recurrence-free survival of patients diagnosed with the TNBC or HER-2+/ER− subtypes [86]. The gene discussed is ERBB2; the disease is breast carcinoma.